Seres Therapeutics Stock Shares Owned By Insiders
| 1S9 Stock | EUR 0.83 0.05 5.68% |
Seres Therapeutics fundamentals help investors to digest information that contributes to Seres Therapeutics' financial success or failures. It also enables traders to predict the movement of Seres Stock. The fundamental analysis module provides a way to measure Seres Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Seres Therapeutics stock.
Seres |
Seres Therapeutics Company Shares Owned By Insiders Analysis
Seres Therapeutics' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Seres Therapeutics Shares Owned By Insiders | 6.66 % |
Most of Seres Therapeutics' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Seres Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 6.66% of Seres Therapeutics are shares owned by insiders. This is 56.13% lower than that of the Healthcare sector and 53.03% lower than that of the Biotechnology industry. The shares owned by insiders for all Germany stocks is 33.99% higher than that of the company.
Seres Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Seres Therapeutics' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Seres Therapeutics could also be used in its relative valuation, which is a method of valuing Seres Therapeutics by comparing valuation metrics of similar companies.Seres Therapeutics is currently under evaluation in shares owned by insiders category among its peers.
Seres Fundamentals
| Return On Equity | -1.9 | |||
| Return On Asset | -0.4 | |||
| Operating Margin | (17.02) % | |||
| Current Valuation | 582.79 M | |||
| Shares Outstanding | 124.59 M | |||
| Shares Owned By Insiders | 6.66 % | |||
| Shares Owned By Institutions | 85.90 % | |||
| Price To Book | 12.02 X | |||
| Price To Sales | 50.23 X | |||
| Revenue | 144.93 M | |||
| Gross Profit | 3.04 M | |||
| EBITDA | (56.72 M) | |||
| Net Income | (65.58 M) | |||
| Cash And Equivalents | 253.62 M | |||
| Cash Per Share | 2.77 X | |||
| Total Debt | 24.64 M | |||
| Debt To Equity | 0.23 % | |||
| Current Ratio | 5.79 X | |||
| Book Value Per Share | 0.54 X | |||
| Cash Flow From Operations | 6.69 M | |||
| Earnings Per Share | (2.18) X | |||
| Target Price | 20.57 | |||
| Number Of Employees | 333 | |||
| Beta | 2.68 | |||
| Market Capitalization | 608.32 M | |||
| Total Asset | 354.86 M | |||
| Z Score | 14.4 | |||
| Net Asset | 354.86 M |
About Seres Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Seres Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Seres Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Seres Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Seres Stock
When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Seres Stock please use our How to Invest in Seres Therapeutics guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.